July 21, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
LAS VEGAS — Customized microperimetry helped researchers track geographic atrophy in patients undergoing CTx001 gene therapy, according to a presentation at Clinical Trials at the Summit. Arshad Khanani, MD, MA, FASRS, of Sierra Eye Associates in Reno, Nevada, presented initial findings from the first cohort of patients enrolled in the phase 1/2 Opti-GAIN study. The primary endpoints
July 21, 2026
2 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

LAS VEGAS — In this Healio Video Perspective, Tarek S. Hassan, MD, professor of ophthalmology at Oakland University William…

DENVER — In a phase 1b trial, subretinal delivery of a human stem cell-derived retinal pigment epithelium yielded visual…

Pegcetacoplan slows photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as…

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

PHOENIX — Screening healthy patients for glaucoma during routine eye exams led to glaucoma referrals that would not have been…

LONG BEACH, Calif. — Patients treated with Encelto who had smaller baseline ellipsoid zone area loss had better treatment…